BPC-157 is sold with confident language about tendon repair, gut healing and faster recovery. Most of that comes from animal work. When researchers searched four databases up to June 1, 2026 for human studies of any kind, they found three, with 30 people in total [5]. None had a comparison group. This page counts that record and explains why the animal results don't settle it. It ends with what a convincing human trial would look like.
Short answer: unknown in humans
The 2026 review judged all three human studies to be of poor methodological quality. It rated the overall certainty of evidence very low, because of serious risk of bias, indirectness and imprecision [5]. Its conclusion was that BPC-157 should not be used clinically outside regulated, high-quality trials.
"Very low" is the bottom grade. It means the true effect may be very different from what the studies report. What BPC-157 is and how it is regulated is on the BPC-157 page.
What the three human studies actually are
Each of the three reported improvement or no problems. None of them could separate the peptide's effect from placebo, time or the clinic's other care.
| Study | Route | People | Design | What it reported | Main weakness |
|---|---|---|---|---|---|
| Lee 2021, knee pain [7] | Injection into the knee, at a clinic | 16 surveyed (17 treated) | Chart review plus phone survey, 6 to 12 months later | 14 of 16 said their pain eased | Recalled pain, no measurement tools, no control group, some also had TB-4 |
| Lee 2024, bladder pain [8] | Injections into the bladder wall during cystoscopy | 12 women | Single-clinic pilot | All 12 rated themselves improved | Self-rated, no control group, one clinic |
| Lee 2025, IV safety [9] | Intravenous infusion | 2 | Safety check over 3 days | No changes in the blood tests used, no side effects reported | Two people, both already users, no efficacy measure |
Counts for the knee study differ by source: the paper treated 17 and surveyed 16 [7], the 2026 review counts 16 [5], and a 2025 review reports 7 of 12 with relief past six months [6].
All three share a lead author and appeared in the same alternative-medicine journal. The details of the joint study are read closely in can BPC-157 help back pain or arthritis.
The colitis trial people cite didn't show a clear difference
The most-cited "controlled" result is a 2005 meeting abstract. It describes 53 people randomized between BPC-157 enema and placebo for two weeks; the exact active-arm count was not reported. Forty-six completed the study [10].
FDA reports mean disease-activity changes of −3.2 points with BPC-157 and −1.6 with placebo. Its reported between-group 95% confidence interval, −4.84 to 1.62, includes zero. Three active-arm and two placebo participants withdrew because of adverse events, mainly worsening colitis according to the abstract authors. FDA concluded the data "are therefore inadequate to support the efficacy and safety" of BPC-157 for colitis [10]. FDA found only the abstract, not a full paper.
Why the animal results don't settle it
A 2025 sports-medicine review found 36 studies through June 2024: 35 preclinical and 1 clinical [6]. In animals, BPC-157 improved healing of muscle, tendon, ligament and bone injuries, and reduced inflammatory signaling. The same review found no clinical safety data. Its authors called BPC-157 promising, while grading every included study at level IV or V, the two lowest levels of evidence.
Animal healing studies often don't hold up in people. Rodents heal differently, the injuries are made in a lab, and the doses and routes don't match what people use. FDA notes that BPC-157 was first made by researchers at the University of Zagreb in the early 1990s [10], and the animal literature grew from there. The sources reviewed here do not establish reproducible controlled human healing benefits.
There is also a gap on routes. FDA found no human data on how BPC-157 is absorbed or cleared after injection under the skin, by mouth, by nasal spray or through the skin [10]. Those are the forms most often sold. Route questions are covered in BPC-157 injected vs oral.
Claimed use by claimed use
| Claimed benefit | Animal evidence | Human evidence | Strength of evidence |
|---|---|---|---|
| Tendon and ligament healing | Many rat studies [6] | None | Very low |
| Knee pain | Not applicable | One survey of 16, no control [7] | Very low |
| Bladder pain (interstitial cystitis) | Not applicable | One pilot of 12, no control [8] | Very low |
| Ulcerative colitis | Rat models | One 2005 abstract, judged inadequate by FDA [10] | Very low |
| Gut healing in general | Animal studies | Nothing beyond the colitis abstract | Very low |
| Muscle growth | Muscle-injury healing in animals | None | None |
| "Reduces inflammation" | Lower inflammatory markers in animals [6] | An eight-week gummy study is registered, but results are not posted [1] | None |
How long people say it takes to work is a separate question, covered in how long does BPC-157 take to work.
What would count as proof
Use this list to judge any new claim you read about BPC-157 or any other peptide:
- People are randomized to the peptide or a placebo.
- Neither the patients nor the assessors know who got what.
- The product is defined: which salt, what purity, what dose and route.
- The main outcome is chosen and registered before the trial starts.
- Results are published in full, not as a meeting abstract.
- Another team gets a similar result.
A registration can describe randomization and masking without supplying results. The available records do not settle efficacy. One randomized, placebo-controlled phase 2 trial in acute hamstring strain began recruiting in China in February 2026 [12]. A second, in recovery after rotator cuff surgery, is listed as not yet recruiting in the US [13]. Neither has results. An earlier oral phase 1 trial registered in 2015 never posted results, and FDA could not find a published paper from it [10].
The current trial search also returns an oral-gummy study marked completed, with 40 participants reported and an eight-week follow-up. It was registered after its reported completion and has no posted results [1]. That record belongs in the research inventory, but it does not establish efficacy or raise the three published studies' certainty.
Where things stand with FDA, in one paragraph
FDA identified no approved BPC-157 product in its review [10]. It left FDA's significant-safety-risk category in April 2026 only because its nominations were withdrawn, not because of new evidence [11]. At a July 2026 advisory meeting, FDA's briefing argued against adding it to the list of substances pharmacies may compound. The FDA meeting page explains that committee recommendations are non-binding [3]. The current 503A list does not include BPC-157 [2]. A peptide-access policy under executive review is pending rather than an issued exemption [4]. In sport, WADA bans BPC-157 at all times [14]. The full status is on is BPC-157 FDA approved, and the risks are on is BPC-157 safe.